FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
haiira nar raananaa.	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Grossman Jerrold B					2. Issuer Name and Ticker or Trading Symbol ADMA BIOLOGICS, INC. [ADMA]									(Ch	Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner					
(Last) (First) (Middle) C/O ADMA BIOLOGICS, INC.			3. Date of Earliest Transaction (Month/Day/Year) 02/11/2020] ⁴	_	cer (give title		10% Owner Other (specify below)				
(Street)	ΓΕ ROUTE Y NJ)7446		4. If <i>i</i>	Amen	dment,	Date o	e of Original Filed (Month/Day/Year)						e) <mark>X</mark> Forn	n filed by O	oup Filing (Check Applicable One Reporting Person Nore than One Reporting			
(City)	(St	ate) (Zip)												Pers			оло ттор	orung	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Di		Date	2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)				and Securiti Benefic Owned		es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership				
							Code	v	Amount	mount (A) or (D)		ice	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)			
Common Stock			02/11/2020				P		22,857(1)	'(1) A \$		3.5	132,864		D					
Common Stock			02/11/2020				P		22,857(1)	22,857 ⁽¹⁾ A \$		3.5	22,857				See Footnote ⁽²⁾			
Common	Stock														31	,381	I		See Footnote ⁽³⁾	
Common Stock														38	,294	I		See Footnote ⁽⁴⁾		
Common Stock											175				See Footnote ⁽⁵⁾					
		Та	ble II -								osed of, convertib				Owned					
Derivative Conversion Date Execution Date, Security or Exercise (Month/Day/Year) if any				ansaction of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)		S (I	. Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	y Ov Fo Dii or (I)	vnership rm: ect (D) Indirect (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
					Code V (A) (D)					able	Expiration Date	Title	Amou or Numb of Share	er						

Explanation of Responses:

- 1. Represents a purchase from the underwriters in the Issuer's public offering.
- 2. These shares are owned by Brookwood LLC ("Brookwood"). The reporting person is the managing member of Brookwood.
- 3. These shares are owned by the Jerrold Grossman 2019 Irrevocable Trust, of which Dr. Grossman serves as investment trustee.
- 4. These shares are owned by Genesis Foundation Inc. ("Genesis"). The reporting person is the President of Genesis.
- 5. These shares are owned by the reporting person's wife.

/s/ Dr. Jerrold B. Grossman, by 02/11/2020 Brian Lenz as Attorney-in-fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.